Ben Taylor Sells 7,956 Shares of Recursion Pharmaceuticals (NASDAQ:RXRX) Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CFO Ben Taylor sold 7,956 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $3.39, for a total value of $26,970.84. Following the transaction, the chief financial officer directly owned 1,180,318 shares of the company’s stock, valued at $4,001,278.02. This represents a 0.67% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Recursion Pharmaceuticals Stock Performance

Shares of Recursion Pharmaceuticals stock opened at $3.37 on Friday. The company has a quick ratio of 5.50, a current ratio of 5.50 and a debt-to-equity ratio of 0.01. The stock has a market cap of $1.78 billion, a PE ratio of -2.28 and a beta of 0.97. The business has a fifty day simple moving average of $3.93 and a 200-day simple moving average of $4.54. Recursion Pharmaceuticals, Inc. has a 12 month low of $2.98 and a 12 month high of $7.18.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its earnings results on Wednesday, February 25th. The company reported ($0.21) EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.07. Recursion Pharmaceuticals had a negative return on equity of 63.98% and a negative net margin of 863.37%.The firm had revenue of $35.54 million for the quarter, compared to the consensus estimate of $24.56 million. During the same quarter in the previous year, the company posted ($0.53) earnings per share. The business’s quarterly revenue was up 671.7% compared to the same quarter last year. On average, sell-side analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. TD Waterhouse Canada Inc. grew its holdings in shares of Recursion Pharmaceuticals by 64.1% in the 2nd quarter. TD Waterhouse Canada Inc. now owns 5,631 shares of the company’s stock valued at $29,000 after acquiring an additional 2,200 shares in the last quarter. Xponance Inc. grew its stake in Recursion Pharmaceuticals by 8.0% in the third quarter. Xponance Inc. now owns 30,020 shares of the company’s stock valued at $146,000 after purchasing an additional 2,221 shares in the last quarter. Main Management ETF Advisors LLC grew its stake in Recursion Pharmaceuticals by 1.7% in the second quarter. Main Management ETF Advisors LLC now owns 142,914 shares of the company’s stock valued at $723,000 after purchasing an additional 2,328 shares in the last quarter. NewEdge Advisors LLC increased its position in shares of Recursion Pharmaceuticals by 28.1% during the 2nd quarter. NewEdge Advisors LLC now owns 11,061 shares of the company’s stock worth $56,000 after purchasing an additional 2,428 shares during the last quarter. Finally, Equitable Holdings Inc. raised its stake in shares of Recursion Pharmaceuticals by 7.1% during the 3rd quarter. Equitable Holdings Inc. now owns 39,400 shares of the company’s stock worth $192,000 after purchasing an additional 2,600 shares in the last quarter. 89.06% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on RXRX. Wall Street Zen raised shares of Recursion Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Saturday, February 28th. JPMorgan Chase & Co. upgraded shares of Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $10.00 to $11.00 in a research report on Wednesday, December 17th. UBS Group set a $11.00 target price on Recursion Pharmaceuticals in a report on Wednesday, December 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Thursday, January 22nd. Finally, Morgan Stanley set a $11.00 price target on Recursion Pharmaceuticals in a report on Wednesday, December 17th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $9.40.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.